Sativex® approved in Sweden for treatment of MS spasticity
Sativex® approved in Sweden for treatment of MS spasticity
GW Pharmaceuticals plc today announced that the Medical Products Agency in Sweden has granted regulatory approval for Sativex® (Delta-9-Tetrahydro-cannabinol (THC) and Cannabidiol (CBD)) oromucosal spray as a treatment of moderate to severe spasticity due to MS in patients who have not responded adequately to other anti-spasticity medicationi. Sativex® is a first in class endocannabinoid system modulator and is currently available in the UK, Germany, Spain and Denmark.
Evidence generated from clinical trials shows that Sativex® has a positive impact on spasticity in multiple sclerosis, while alleviating associated symptoms including pain, bladder or sleep disturbance. By relieving the symptoms of MS, Sativex® can improve patients' quality of life and allow them greater independence in performing their daily activities.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1814
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1043 Views
-
Last post by frodo
-
- 5 Replies
- 1405 Views
-
Last post by jimmylegs
-
- 5 Replies
- 2412 Views
-
Last post by Jaded
-
- 0 Replies
- 4355 Views
-
Last post by NHE
-
- 0 Replies
- 2672 Views
-
Last post by NHE
-
- 0 Replies
- 2143 Views
-
Last post by frodo
-
- 0 Replies
- 2422 Views
-
Last post by Cece
-
- 2 Replies
- 1209 Views
-
Last post by NHE